Rights statement: This document is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Health Visiting, copyright © MA Healthcare, after peer review and technical editing by the publisher. To access the final edited and published work see http://www.journalofhealthvisiting.com/cgi-bin/go.pl/library/article.cgi?uid=108927;article=hv_6_9_440_446.
Accepted author manuscript, 713 KB, PDF document
Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - Patterns of prescribing in the management of gastro-oesophageal reflux in infants in Scotland
AU - Cowie, Jean
AU - Holland, Paula Jane
AU - Pirie, Iain
AU - Milligan, Christine
N1 - This document is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Health Visiting, copyright © MA Healthcare, after peer review and technical editing by the publisher. To access the final edited and published work see http://www.journalofhealthvisiting.com/cgi-bin/go.pl/library/article.cgi?uid=108927;article=hv_6_9_440_446.
PY - 2018/9/20
Y1 - 2018/9/20
N2 - The aim of this study was to determine trends over time and geographical differences in prescribing for gastro-oesophageal reflux (GOR) and gastro-oesophageal reflux disease (GORD) in infants aged 0-1 year in Scotland. National prescribing data obtained from the Information Services Division of NHS Scotland (ISD Scotland) was quantitatively analysed using the software tool Minitab16. Prescribing of the three key medicines, alginate, omeprazole and ranitidine, used in the management of GOR and GORD in infants aged 0-1 year increased in Scotland over the 7 years between 2010 and 2016. The rise in the prescribing rates of alginate, omeprazole and ranitidine is a cause for concern given the uncertainty regarding the efficacy of these medicines in this age group, and that omeprazole and ranitidine are not licensed for use in infants under 1 year of age in the UK. While the data suggest that the prescribing rate of alginate may have stabilised, the increasing trends for omeprazole and ranitidine show no sign of abating and this may have financial implications for the NHS, as well as potential ethical and health implications for young infants.
AB - The aim of this study was to determine trends over time and geographical differences in prescribing for gastro-oesophageal reflux (GOR) and gastro-oesophageal reflux disease (GORD) in infants aged 0-1 year in Scotland. National prescribing data obtained from the Information Services Division of NHS Scotland (ISD Scotland) was quantitatively analysed using the software tool Minitab16. Prescribing of the three key medicines, alginate, omeprazole and ranitidine, used in the management of GOR and GORD in infants aged 0-1 year increased in Scotland over the 7 years between 2010 and 2016. The rise in the prescribing rates of alginate, omeprazole and ranitidine is a cause for concern given the uncertainty regarding the efficacy of these medicines in this age group, and that omeprazole and ranitidine are not licensed for use in infants under 1 year of age in the UK. While the data suggest that the prescribing rate of alginate may have stabilised, the increasing trends for omeprazole and ranitidine show no sign of abating and this may have financial implications for the NHS, as well as potential ethical and health implications for young infants.
M3 - Journal article
VL - 6
SP - 440
EP - 446
JO - Journal of Health Visiting
JF - Journal of Health Visiting
SN - 2050-8719
IS - 9
ER -